Organic Active Ingredients TRIZ Cases

Selective amino quinazoline P2X3 inhibitors address cough, asthma, IPF, and COPD through targeted receptor blockade.

Selective 1,3,4-oxadiazole compounds inhibit HDAC6 to reduce off-target toxicity while maintaining bioavailability for cancer and inflammatory therapy.

Biopterin compounds inhibit iNOS to lower extracellular glutamate and lactate, helping protect brain cells from excitotoxic injury.

Deuterium-substituted phenylalkylamines modulate monoamine targets to keep therapeutic effects while improving action duration and tolerability.

Selective allosteric AKT inhibition addresses HHT vascular malformations where PI3K or mTOR inhibitors fall short, with lower-dose safety.

Bicyclic amines inhibit CDK2 to treat cancers with deregulated kinase activity and may restore trastuzumab sensitivity in resistant HER2+ tumors.

Amorphous lumateperone oral forms use stabilizing excipients to speed onset and support combination therapy for acute CNS disorders.

Ionic bonding between anthocyanin and fucoidan improves in vivo stability and solubility, boosting immune activity and reducing anticancer side effects.

Using glutathione or its salt to raise in vivo nitric oxide helps address vascular endothelial dysfunction and promote vasodilation.

Pre-dosing methotrexate before pegloticase suppresses antibody formation, reducing infusion reactions and prolonging urate lowering in refractory gout.

Small molecules block the RING1B-BMI1 E3 ligase in PRC1 to target chemotherapy-resistant leukemia stem cells and related cancers.

A cyclophilin A-mediated tri-complex creates a new Ras(ON) binding pocket and blocks effector binding to inhibit oncogenic signaling.

Bivalent HPK1 degraders recruit proteasomal machinery to lower protein levels, addressing resistance left by enzyme-only inhibition.

Gene knockouts and added human immune-regulating proteins help pig organs resist rejection and expand transplantable tissue supply.

Multiple macrocyclic solid forms, salts, and solvates improve farnesyltransferase inhibitor formulation and support cancer treatment efficacy.

A protected-intermediate and crystallization route cuts harsh conditions and chromatography, enabling scalable high-purity Nebivolol production.

Low-dose arginine oral care accelerates HSP 27 expression to reduce inflammation and support healing of damaged oral tissue.

Novel CFTR modulators aim to improve response across mutations while reducing side effects and supporting longer-term respiratory treatment.

A scalable route uses key intermediates to make KRAS G12C inhibitors that address treatment resistance in KRAS-mutated cancers.

A bicyclic RET inhibitor improves selectivity against RET-mutant cancers while reducing side effects and helping address drug resistance.

A modified cyclosporin compound helps prevent infection-linked lung injury while reducing inflammation and avoiding cyclosporin A limits.

Intravesical paclitaxel linked to hyaluronic acid targets CIS in BCG-refractory NMIBC while minimizing systemic absorption and toxicity.

A fused cyclic CRBN modulator drives Wee1 ubiquitination and proteasome degradation, expanding substrate targeting beyond standard IMiD drugs.

Small molecules broaden KRAS inhibition beyond G12C to G12D, G12V, G13D, and WT KRAS, supporting cancer therapy across more mutation types.

Waxy lipid shells with surfactant and metastability regulators keep silicon particles uniform and phase-stable for dermal active delivery.

Formula (I) compounds inhibit KIF18A to trigger mitotic arrest and apoptosis, addressing the lack of target-specific cancer therapies.

A fluorinated benzothiazole or benzofuran probe improves α-synuclein aggregate selectivity for brain imaging and aggregation inhibition.

A polyphenol-rich feijoa extract uses solvent extraction and resin adsorption to reduce glucose, lipids, blood pressure, and inflammation.

Low ER and elevated PD-L1 identify HER2-positive patients who may benefit from adding PD-L1 cotherapy to trastuzumab and docetaxel.

Small molecules bind ATXN3 pre-mRNA to shift splicing, lower full-length Ataxin-3, and address Spinocerebellar Ataxia 3.

A low-cost oral Citrus depressa extract promotes corneal nerve regeneration, tear secretion, and wound repair with fewer side effects.

Dual-binding KRAS G12C compounds inhibit both GDP- and GTP-bound forms to counter resistance from increased GTP-bound signaling.

Antisense oligomers induce non-productive PPIF splicing to lower CYPD function while avoiding off-target effects on other cyclophilins.

Small molecules block NSD1, NSD2, and NSD3 methyltransferase activity to curb aggressive tumor progression where current therapies fall short.

Blocking TEAD-complex2 formation improves homologous recombination repair, helping treat HR-deficient tumors and boost CRISPR editing.

Modified branched polymers form stable taxane nanoparticles that improve solubility and bioavailability while avoiding toxic solubilizing agents.

Giving a CD73-upregulating agent before glucocorticoids preserves organ-protective adenosine signaling and lowers SIRS mortality.

Novel lipase inhibitors reduce free fatty acid-driven lipotoxicity in pancreatitis while avoiding repeated dosing and lowering toxicity risks.

Periodic SMARCA4/SMARCA2 inhibitor dosing suppresses tumor growth and apoptosis while reducing toxicity from continuous treatment.

Lipid-delivered RNA antigens target dendritic cells to trigger melanoma-specific T-cell responses in refractory tumors and support checkpoint therapy.

LMK235 suppresses HDAC5 in trigeminal ganglia neurons to reverse epigenetic pain changes and durably reduce hypersensitivity.

pH-sensitive linker-core acid prodrugs stay stable in blood but accumulate in acidic tumors, improving efficacy while limiting healthy tissue exposure.

A defined blend of 5 HMOs, bGOS, and lcFOS boosts bifidobacteria, lowers Enterobacteriaceae, and strengthens the intestinal barrier.

Removing silicone oil from prefilled syringe surfaces helps prevent RNA agglomeration and preserve lipid-based RNA formulation stability.

Targeted PAI-1 inhibitor compounds help control thrombosis and fibrosis while improving lipid metabolism through higher HDL and lower VLDL.

Biomarker screening identifies asymptomatic subjects at risk, enabling early antifibrotic treatment to delay fibrotic lung disease onset.

Triazolopyridazine compounds improve Rac1 inhibition below 1.0 μM while maintaining selectivity over 90 kinases and better pharmacokinetic properties.

Targeted ASBT inhibition with maralixibat at 300-1200 μg/kg/day reduces pruritus and serum bile acids in rare cholestatic liver disease.

Replacing uracil in microRNA with 5-halouracil boosts stability and anticancer potency while reducing toxicity and resistance.

Aliphatic acid ester prodrugs keep hexahydro-beta-acid feed additives stable during storage and high-temperature pelleting while preserving breeding effects.